Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial.
Jay S PeposePaul J HartmanHarvey B DuBinerMarc A AbramsRobert J Smyth-MedinaSayoko E MoroiAlan R MeyerMina P SoochReda M JaberKonstantinos CharizanisSeth A KlapmanArin T AminJonah E YousifEliot S LazarPaul M KarpeckiCharles B SlonimMarguerite B McDonaldPublished in: Clinical ophthalmology (Auckland, N.Z.) (2021)
Although mean IOP was not lowered significantly, daily evening dosing of 1% PMOS was found to be well tolerated with no daytime conjunctival redness and demonstrated improvement in DCNVA with sustained PD reduction in a glaucomatous and presbyopic population. Smaller pupil size can have beneficial effects in improving symptoms of presbyopia and DLD, which will be the focus of further studies.